FDA’s disease area meetings under the patient-focused drug development initiative are providing the agency with a better understanding of not only the hallmark symptoms associated with a given condition. At the March 26 fibromyalgia patient meeting lesser known symptoms that drug reviewers may not previously have been aware of also came to light.
The fibromyalgia meeting was the sixth of 20 disease area meetings to be conducted under the PDUFA V program aimed...